Evidence map›Paper›PMID 41112724›Full record

ReviewMedComm2025

Aryl Hydrocarbon Receptor in Health and Disease.

Haonan Li, Yufeng Fan, Jizheng Liu, Shumin Dong, Bin Wen, Yunfei Zhang, Xiaocui Wang, Xuemei Duan, Ying Hu, Ze Yan and 2 more

Abstract readReview
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. The aryl hydrocarbon receptor, CIITA and HLA-II: who is watching the watchdog?Journal of experimental & clinical cancer research : CR · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Food preservative tBHQ modulates Th17/TCurrent research in toxicology · 2026
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haonan LiDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Yufeng FanDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Jizheng LiuThe Second People's Hospital of Liaocheng Liaocheng China.
Shumin DongDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Bin WenDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Yunfei ZhangDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Xiaocui WangDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Xuemei DuanDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Ying HuDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.
Ze YanAcademy of Medical Sciences Shanxi Medical University Taiyuan China.
Huifeng ShangDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.ORCID https://orcid.org/0000-0001-6409-1157
Yukai JingDepartment of Clinical Laboratory Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AhR) functions as a ligand-dependent transcription factor, serving as a pivotal environmental sensor that significantly influences both physiological and pathological processes. The inactivated state of AhR is present in the cell cytoplasm and transfer into the nucleus upon activation by a variety of ligands. It subsequently regulates a variety of processes including cellular metabolism, organ and tissue development, and maintenance of immune homeostasis. Despite substantial advancements over the past decade, the mechanisms by which AhR specifically regulates immune cell function in response to environmental factors and influences disease progression remain not fully elucidated. This review systematically analyzes the basic structure and major signaling pathways of AhR, its physiological functions in maintaining organismal homeostasis and its mechanism of action on various types of immune cells, and their therapeutic potential in autoimmune diseases, inflammatory disorders, tumor microenvironment, and neurodegenerative diseases. Translating immune-metabolic reprogramming mechanisms into clinical applications represents a pivotal challenge in AhR research. And this review integrates and analyzes the great potential of AhR as a pleiotropic therapeutic target for regulating immunity and treating a series of diseases, offering actionable frameworks for future exploration.

Indexed as

AhRimmune cellssignaling pathwaystreatment strategies

Identifiers

PMID41112724
PMCPMC12531456

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.